The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection

Cancer constitutes one of the most urgent global health crises, with over 20 million new cases diagnosed annually worldwide, claiming 10 million lives. This devastating burden disproportionately affects vulnerable populations: 75% of cancer deaths occur in low- and middle-income countries despite these regions having lower reported incidence rates. Lung cancer leads the global toll, representing 12% of all cases but 19% of deaths, followed by breast cancer (12% of cases) and colorectal cancer (9.6%). A stark geographical inequity defines the cancer landscape-while wealthy regions such as North America, Northern Europe and Australia report the highest incidence rates, Africa and Latin America suffer the highest mortality rates. This disparity will intensify dramatically: cancer deaths in low-income countries are projected to surge 155% compared to just 56% in high-income nations by 2050. The financial devastation compounds this crisis, with 56% of patients worldwide facing catastrophic health expenditures extending beyond medical costs to include lost income and reduced productivity. Economic burden varies starkly by wealth: 75% of patients in low-income countries experience financial catastrophe versus 58% in middle-income countries and 26% in high-income nations. However, cancer prevention offers unprecedented opportunities to transform this crisis through interventions we already possess. From largely preventable infectious cancers like stomach and cervical malignancies, to lifestyle-driven epidemics including lung and colorectal cancers, to complex multifactorial diseases like breast cancer. Evidence-based prevention strategies can dramatically reduce suffering while generating massive healthcare savings. Emerging genetic technologies amplify this potential: universal genetic testing and pharmacogenomics now enable identification of high-risk individuals before disease develops, allowing targeted prevention while optimising treatments based on individual genetic profiles. Cancer prevention represents not merely a health opportunity but an economic imperative. The primary barrier is no longer scientific understanding but systematic implementation. Governments, policymakers, insurance companies and the public urgently need clearer evidence and education demonstrating proven successes to motivate decisive action toward creating healthier populations and reducing cancer burdens worldwide.